Most peptides discussed in the biohacking and performance community have one thing in common: their most popular applications have never been tested in humans. TB-500 for tendons. BPC-157 for gut healing. FOXO4-DRI for senolysis. The preclinical data is interesting, the human data is absent, and the community proceeds anyway.
ARA-290 is the opposite situation. It has demonstrated actual structural nerve fiber regeneration in a properly controlled human trial. A pre-specified primary endpoint met. 23% increase in measurable new nerve fibers in 28 days. FDA Fast Track and Orphan Drug designations. A successful end-of-Phase 2 FDA meeting completed.
Nobody in the biohacking space is covering it.
ARA-290 (also called cibinetide) is a synthetic peptide derived from the helix-B surface domain of erythropoietin (EPO). EPO is best known as the hormone that stimulates red blood cell production, and as a performance-enhancing drug abused in endurance sports. ARA-290 is not EPO. It is an 11 amino acid fragment engineered specifically to separate EPO's tissue-protective effects from its hematopoietic effects.
The key distinction is the receptor. EPO stimulates red blood cell production by activating a homodimeric EPO receptor complex. The tissue-protective effects of EPO are mediated by a completely different receptor: a heterodimeric complex composed of the EPO receptor and CD131, the beta-common cytokine receptor. This second receptor is also known as the innate repair receptor (IRR). ARA-290 selectively activates the IRR without touching the hematopoietic receptor complex. The result is tissue protection, anti-inflammation, and nerve repair without any increase in hematocrit, hemoglobin, or clotting risk.
This pharmacological separation is the reason ARA-290 exists. EPO's tissue-protective mechanism is real and compelling, but direct EPO therapy in non-anemic patients carries serious cardiovascular risks. ARA-290 accesses the same downstream biology without those risks.
ARA-290 acts on the innate repair receptor, which is rapidly upregulated locally following tissue injury. Despite a short plasma half-life, ARA-290 triggers sustained biological effects when concentrations exceed the low nanomolar affinity of the receptor. The peptide acts like a trigger rather than a continuous agent, briefly activating the IRR to initiate a cascade of tissue-protective events that outlast the peptide's presence in circulation.
The downstream effects include reduction in pro-inflammatory cytokines via NF-kB inhibition, protection of mitochondria and cell membranes from oxidative stress, activation of repair pathways in neurons and endothelial cells, and suppression of the NLRP3 inflammasome in Schwann cells during the acute phase of nerve injury.
A second mechanism operates entirely separately from IRR activation: TRPV1 channel antagonism on small nerve fibers. TRPV1 is the receptor involved in mechanical hypersensitivity and neuropathic pain. ARA-290 blocks it directly, addressing pain through a pathway distinct from the repair mechanism. The compound is doing two different things simultaneously: repairing damaged nerve fibers via the IRR, and relieving hypersensitivity via TRPV1 antagonism.
This dual mechanism means ARA-290 is not acting as an analgesic in the conventional sense. It is not masking pain signals. It is reducing the underlying inflammatory pathology that generates them while simultaneously stimulating structural repair of the nerve fibers themselves.
The strongest data for ARA-290 comes from a Phase 2b randomized controlled trial in patients with sarcoidosis-associated small fiber neuropathy. Sarcoidosis is a systemic inflammatory disease that commonly causes small fiber neuropathy, the damage of unmyelinated C-fibers and thinly myelinated A-delta fibers that control pain and autonomic function. Standard anti-inflammatory therapy often fails to restore nerve function.
The trial enrolled 64 participants and was double-blind, placebo-controlled. The pre-specified primary endpoint was change in intraepidermal nerve fiber density, measured by skin punch biopsy. After 28 days of ARA-290 treatment, treated patients showed a 23% increase in GAP-43-positive nerve fibers compared to placebo.
GAP-43 is a marker of newly generated nerve fibers, specifically associated with active axonal growth. This is not a pain score. It is not a subjective outcome. It is a measurable structural biological endpoint demonstrating that new nerve fibers grew in response to treatment. The endpoint was pre-specified, the trial was properly controlled, and the result was statistically significant.
Secondary endpoints confirmed functional translation: the improvements in intraepidermal nerve fiber density correlated with improvements on the 6-minute walk test, connecting the structural finding to a functional outcome.
FDA granted ARA-290 Fast Track designation and Orphan Drug designation for sarcoidosis-associated neuropathy following this data. A successful end-of-Phase 2 meeting with the FDA has been completed. Phase 3 funding is the only remaining gap between this evidence and a full clinical program.
A Phase 2 trial enrolled 49 patients with type 2 diabetes and peripheral neuropathy. Results showed nerve fiber regrowth alongside improvements in metabolic control parameters. The mechanistic rationale is particularly coherent here: the same inflammatory pathways that ARA-290 targets via the IRR are the same pathways driving diabetic nerve damage. The compound is addressing the pathology, not masking it.
Human islet data combined with animal transplant studies showed allograft survival of 19.3 days versus 1.4 days in controls. EU Orphan designation was granted for this indication. The mechanism is anti-apoptotic protection of transplanted islet cells via caspase 3/7 suppression during cytokine exposure, the inflammatory environment that destroys transplanted islets.
An incidental finding from the diabetic macular edema Phase 2 trial (n=9) is worth noting separately. The trial missed its primary visual endpoints but showed 100% improvement in albuminuria in treated patients, an unexpected and potentially important signal for a renal protection indication. ARA-290 accumulates in renal tissue and a dedicated renal protection trial is scientifically well-justified.
ARA-290 is not sold by research peptide vendors in the same volume as BPC-157 or TB-500. It does not have the cultural footprint of the GH secretagogues. The applications it has the strongest evidence for, sarcoidosis neuropathy and diabetic peripheral neuropathy, are not the performance and longevity applications that drive most community interest.
The result is a compound with Phase 2b human evidence meeting a structural primary endpoint that receives a fraction of the attention given to compounds with no human data at all.
The longevity and aging applications of ARA-290 are worth watching specifically because the cardiac aging preclinical data is among the best-designed in this compound class. A 15-month formal randomized controlled trial in aged rats demonstrated reduced cardiac inflammation and attenuated age-associated heart function decline. That is not a standard 4-week mouse study. The beta-common receptor mechanism underlying it is the same receptor already validated in humans for nerve regeneration.
ARA-290 does not have broad approval. The FDA Fast Track and Orphan Drug designations apply to sarcoidosis-associated neuropathy, a rare disease. The Phase 3 program has not been funded. The longevity, cardiac aging, and stroke applications are preclinical.
The diabetic macular edema trial missed its primary visual endpoints, and n=9 is a small sample from which limited conclusions can be drawn.
Community protocols using subcutaneous injection are extrapolated from intravenous clinical trial protocols. No published pharmacokinetic study has validated the SubQ route or established the optimal dosing interval for that administration method.
Blood-brain barrier penetration has not been formally characterized in humans, which limits conclusions about the neuropsychiatric and stroke applications despite the mechanistic rationale.
ARA-290 is the most clinically mature uninvestigated peptide in The Peptide Signal database. By clinically mature, the meaning is specific: it has met a structural primary endpoint in a properly controlled human trial, holds regulatory designations reflecting that evidence quality, and has completed the end-of-Phase 2 FDA process that precedes Phase 3 initiation.
The fact that it receives less attention than compounds with no human data at all is the clearest example of the gap between evidence quality and community visibility in the peptide space.
Phase 3 funding is the next step. If that trial is conducted and the sarcoidosis SFN data holds at scale, ARA-290 would become the first peptide in this compound class with demonstrated nerve regeneration across both Phase 2 and Phase 3 human trials.
The full ARA-290 evidence profile, covering all nine researched applications with complete use case analysis, mechanism deep dive, dosing context from published trials, and comparative notes against BPC-157 and SS-31, is available to Signal Pro subscribers.
Culver DA, et al. (2017). Cibinetide treats small fiber neuropathy in sarcoidosis. Respiratory Medicine.
Brines M, et al. (2015). ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine.
Rizzo MA, et al. (2010). Cibinetide increases pancreatic islet transplant survival. American Journal of Transplantation.
Dahan A, et al. (2013). ARA 290, an innate repair receptor ligand, reduces neuropathic pain. Anesthesiology.
Swartjes M, et al. (2011). ARA290 prevents and relieves neuropathic pain in rats. Anesthesiology.
Brines M, et al. (2008). Cibinetide is a small, nonerythropoietic EPO-mimetic peptide that activates tissue protective pathways. Molecular Medicine.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use